Vaxcyte (PCVX) Gains from Investment Securities (2019 - 2020)
Vaxcyte (PCVX) posted quarterly Gains from Investment Securities of $179000.0 for Q1 2020, up 79.0% quarter-over-quarter from $100000.0 in Q3 2019.
Powered by 
Analysis
Vaxcyte (PCVX) Gains from Investment Securities (2019 - 2020) Analysis & Trends
Vaxcyte (PCVX) has reported Gains from Investment Securities for 2 consecutive years, with $179000.0 the latest figure, recorded in Q1 2020.
- In Q1 2020, Gains from Investment Securities changed N/A year-over-year to $179000.0; the TTM figure through Dec 2020 stood at $179000.0 (changed N/A YoY), while the FY2020 annual figure was $179000.0, up 1591.67% from the prior year.
- Gains from Investment Securities rose to $179000.0 in Q1 2020 per PCVX's latest filing, from $100000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $179000.0 in Q1 2020 and bottomed at -$200000.0 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Vaxcyte | 8.83 Bn | 8.83 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 179,000.00 |
| Sep 30, 2019 | 1.00 Mn |
| Jun 30, 2019 | -200,000.00 |